The IVR, prepared by an international team of experts, provides a focused blueprint for action that will allow the global influenza community to apply the lessons learned from COVID-19 vaccine development as a springboard for launching a new era for influenza vaccine research and development.
Threats from seasonal and pandemic influenza persist in a world still battling the COVID-19 pandemic. As another highly contagious respiratory virus, influenza causes a spectrum of disease, ranging from mild to fatal. Globally, influenza kills up to 650,000 people every year and causes serious illness in some 5 million. In addition to causing respiratory problems, the flu can also significantly increase risks of suffering a heart attack or stroke. Novel influenza strains also periodically emerge to cause devastating pandemics. According to some models, nearly 33 million people could be killed within the first 6 months of a severe flu pandemic. CIDRAP is a global leader in addressing public health preparedness and emerging infectious disease response. This IVR effort, funded by Wellcome, also involved extensive input from an expert task force and engagement of more than 100 stakeholder organizations in 29 countries around the globe through extensive discussions, document review, and consensus-building.
L’Oréal-UNESCO Awards for women goes to pioneering work in environmental and life sciences
UNESCO and the L’Oréal Foundation have unveiled the winners of this year’s International Prize for Women in Science, which honours five eminent women scientists with exceptional careers from the five regions of the world, as it has done annually since 1998.
Esta historia es de la edición October 2021 de Future Medicine India.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 2021 de Future Medicine India.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
Early Reports On Omicron Encouraging: Anthony Fauci
Even as the Omicron variant of coronavirus is spreading across the world quickly, early reports suggest that it may cause less severe disease than the Delta variant, says Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, US.
Air Pollution Reduces 8 Years Of Life Expectancy In India
India registers 18 percent of deaths annually due to air pollution and related diseases, while nationwide socioeconomic inequalities persist in asthma diagnosis across India
Importance Of Adhering To Covid Appropriate Behaviour
As the efficacy of existing vaccines has been proven to be inadequate against Omicron, our only hope from the jab is to reduce the severity of the disease, highlighting the importance of adhering to covid appropriate behaviour
AstraZeneca's new covid drug AZD7442 shows 83% prevention and 88% treatment efficacy
AstraZeneca, which announced the latest data from Phase III trials of its new Covid-19 drug -- AZD7442 -- said both the prevention and outpatient treatment studies showed robust efficacy from a onetime intramuscular (IM) dose of the long-acting antibody combination.
VACCINES IN YOUR POCKET
DR. SAUMYA SWAMINATHAN Cheif Scientist, World Health Organisation
DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA
The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs
EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY
The active cases have come down as compared July leveld, the threat of new variants is looming large.
END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS
Forty years after the first AIDS case was reported, and 35 years since the first case in India, HIV still threatens us. Today, the world is off track from delivering on the shared commitment to end AIDS by 2030.
CONVENTIONAL LINEN IS ONE OF THE BIGGEST CULPRITS IN HOSPITAL ACQUIRED AS WELL AS SURGICAL SITE INFECTIONS
The ‘green colour’ linen is synonymous with hospitals, as it has been in use for centuries in hospitals world over, especially the conventional healthcare settings. But how many, even in the medical community, are really conscious about the responsibility for and the critical role of this piece of medical accessory in ensuring patient safety? Evidence from most hospitals in India indicates that not many are aware of the standards, and even if they are, not many bother with them. Again, going by real world experience, there exists another paradox. Though the actual cost of the repeated use of the linen is higher than the cost of single-use disposables (recommended in modernday care), it is still being used in a large majority of hospitals and clinics in India — because it is the convention. Therefore, transformation hesitance is more of a mindset issue rather than ignorance or economics. Most in the industry also oppose quality regulations in the country. In a market where hundreds of textile weavers and cloth merchants turned medical mask and accessory manufacturers overnight during the Covid pandemic, the market situation serves the unscrupulous minds who only eye the profits. However, there are a handful of local companies, besides the large organised players, who stick to quality products in this predominently price conscious market due to internal SOPs or pure commitment. For JAMES GEORGE, Founder and Managing Director at Kochi-based Careon Healthcare Solutions, it is more of a personal commitment. In a freewheeling interview with Editor CH UNNIKRISHNAN, George says that the primary reason behind the rise of unscrupulous players in the medical disposables market is lack of awareness among the users and the patients. Edited excerpts:
UK approves sotrovimab as new covid treatment for high risk adults
The Medicines and Healthcare Products Regulatory Agency (MHRA), the drug regulator of the UK, has approved sotrovimab, branded as Xevudy, a new biological drug to fight Covid-19. The drug was found effective to reduce the likelihood of hospital admission and death by about 79 percent in high-risk adults.
